Blue Water Vaccines Inc. (BWV) successfully completed its initial public offering (IPO) on February 23, 2022, raising approximately $20 million from selling 2,222,222 shares at a price of $9.00 per share. The shares began trading on the Nasdaq under the ticker symbol BWV on February 18, 2022. Boustead Securities, LLC was the sole book-running manager for the offering. The IPO aims to support the company's development of innovative vaccines addressing significant health challenges globally, including a universal flu vaccine and a candidate for pneumococcus.
Blue Water Vaccines (BWV) has priced its initial public offering (IPO) at $9.00 per share, offering 2,222,222 shares and aiming for gross proceeds of approximately $20 million. Trading on the Nasdaq under the ticker BWV is set to begin on February 18, 2022, with the IPO expected to close on February 23, 2022. Boustead Securities acts as the sole book-running manager for the offering. The company's focus is on developing vaccines, including a universal flu vaccine and a pneumococcus vaccine for children, leveraging proprietary technology from established medical institutions.